Omapatrilat OverviewOmapatrilat (INN, proposed trade name Vanlev) is an experimental antihypertensive agent that was never marketed. It inhibits both neprilysin (neutral endopeptidase, NEP) and angiotensin-converting enzyme (ACE). NEP inhibition results in elevated natriuretic peptide levels, promoting natriuresis, diuresis, vasodilation, and reductions in preload and ventricular remodeling. It was discovered and developed by Bristol-Myers Squibb but failed in clinical tria...
Read more Omapatrilat Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Omapatrilat
Recent Omapatrilat Forums:Be the first to start a discussion about this drug.
Other drugs which contain Omapatrilat or a similar ingredient: (1 result)
- VANLEV Omapatrilat